Home > Insider Trading > Filing (0001104659-20-004440)

Filing Details

Accession Number:: 0001104659-20-004440
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-01-15 21:53:59
Reporting Period:: 2020-01-10

Accepted Time:: 2020-01-15 21:53:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777652	Versant Ventures Vi Gp-Gp, Llc	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777654	Versant Ventures Vi Gp, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-01-10	19,343	$20.10	3,183,724	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-01-13	11,593	$20.16	3,172,131	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-01-13	83	$20.84	3,172,048	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-01-14	12,307	$20.00	3,159,741	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-01-15	7,511	$19.73	3,152,230	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
These sales were executed in multiple trades at prices ranging from $19.80 to $20.28. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These sales were executed in multiple trades at prices ranging from $19.76 to $20.72. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These sales were executed in multiple trades at prices ranging from $19.71 to $20.33. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These sales were executed in multiple trades at prices ranging from $19.67 to $19.86. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein.